Pediapharm (fka )

[BioSpecialist]

This Undiscovered Company has 6 Drugs on Market and 5 under review by Health Canada . The Game Changer for Pediapharm is Easyhaler which expected to approved before year end .Another reason to own the Stock is the upcoming US-Partnership for Naproxen which also expected before year end . This Stock is a Lifetime Opportunity .


Pediapharm (PDP)

MarketCap: C$ 22.2 Millionen
Cash: $5.5 Millionen

Price: $0.31


Nice Summary (Fact Sheet)
http://www.pedia-pharm.com/wp-content/themes/ifeature-tpl/PDF/PDP_Fact_sheet_oct_26_2015.pdf




Pediapharm has submitted its reconsideration package to Health Canada regarding Easyhaler Budesonide. The Company’s objective remains to obtain a marketing approval by the end of 2015.


Furthermore, before the end of 2015, the Company intends to sign an agreement with a US commercial partner for the selling and marketing of its first product acquisition in the US; namely the Pediapharm Naproxen Suspension. Pediapharm believes that with this agreement, the Company will reach profitability more rapidly.